BioLife Solutions (NASDAQ:BLFS) Insider Karen Foster Sells 519 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) insider Karen Foster sold 519 shares of the business’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $25.13, for a total transaction of $13,042.47. Following the transaction, the insider directly owned 192,319 shares in the company, valued at approximately $4,832,976.47. The trade was a 0.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

BioLife Solutions Price Performance

BioLife Solutions stock traded up $0.68 during midday trading on Thursday, hitting $25.69. 53,084 shares of the stock were exchanged, compared to its average volume of 443,760. BioLife Solutions, Inc. has a 1 year low of $19.10 and a 1 year high of $29.62. The firm has a market cap of $1.24 billion, a P/E ratio of -368.03 and a beta of 1.93. The company has a 50 day moving average price of $26.34 and a two-hundred day moving average price of $24.52.

Institutional Investors Weigh In On BioLife Solutions

A number of institutional investors have recently made changes to their positions in the company. State of Wyoming lifted its stake in BioLife Solutions by 353.1% during the first quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider’s stock worth $44,000 after purchasing an additional 1,490 shares during the last quarter. Hantz Financial Services Inc. increased its stake in BioLife Solutions by 54.1% during the third quarter. Hantz Financial Services Inc. now owns 1,877 shares of the medical equipment provider’s stock valued at $48,000 after purchasing an additional 659 shares during the last quarter. US Bancorp DE raised its holdings in shares of BioLife Solutions by 243.7% during the first quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider’s stock worth $49,000 after purchasing an additional 1,528 shares during the period. Quarry LP lifted its position in shares of BioLife Solutions by 50.9% in the 3rd quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock worth $54,000 after buying an additional 713 shares during the last quarter. Finally, Ameritas Investment Partners Inc. boosted its holdings in shares of BioLife Solutions by 12.8% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock valued at $83,000 after buying an additional 441 shares during the period. 93.24% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently commented on BLFS. Zacks Research cut BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 8th. HC Wainwright restated a “buy” rating and set a $32.00 price objective on shares of BioLife Solutions in a report on Monday, November 24th. Wall Street Zen cut BioLife Solutions from a “buy” rating to a “hold” rating in a research note on Sunday, November 30th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of BioLife Solutions in a research report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $30.75.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.